- Conditions
- Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
- Interventions
- Laboratory Biomarker Analysis, Selumetinib, Temsirolimus
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Duarte, California • Los Angeles, California + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1537–1560
of 10,645
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Opioid Misuse
- Interventions
- Brief Intervention Medication Therapy Management, Standard Medication Counseling (SMC)
- Behavioral
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Somerset, Pennsylvania
- Conditions
- Bacteremia, Pseudomonas Infections
- Interventions
- Blood draws, Blood draw
- Procedure · Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Liver Cancer
- Interventions
- arsenic trioxide
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Prodromal Symptoms, Prodromal Stage, Prodromal States, Psychosis
- Interventions
- Cognitive Behavioral Therapy
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 13 Years to 19 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- VHL - Von Hippel-Lindau Syndrome, VHL Gene Mutation, VHL Syndrome, VHL Gene Inactivation, VHL-Associated Renal Cell Carcinoma, VHL-Associated Clear Cell Renal Cell Carcinoma
- Interventions
- Belzutifan
- Drug
- Lead sponsor
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 8
- States / cities
- Bethesda, Maryland • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
- Conditions
- Cognitive Disorders, HIV Infections
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 25
- States / cities
- Menlo Park, California • San Diego, California • San Francisco, California + 17 more
- Conditions
- Alport Syndrome
- Interventions
- Placebo Oral Capsule, Bardoxolone Methyl
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 32 more
- Conditions
- Neurodevelopmental Abnormality
- Interventions
- Randomized to Umbilical Cord Milking at birth, Randomized to Delayed Cord Clamping at birth
- Procedure
- Lead sponsor
- Sharp HealthCare
- Other
- Eligibility
- 22 Months to 42 Months
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 10 more
- Conditions
- COVID-19, SARS-CoV-2
- Interventions
- AZD1222, Placebo
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 32,450 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 78
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 66 more
- Conditions
- Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
- Interventions
- Berzosertib, Carboplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 11 more
- Conditions
- Multiple Myeloma
- Interventions
- Cilta-cel OOS Therapy
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 137
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Goodyear, Arizona + 96 more
- Conditions
- Hepatitis C
- Interventions
- SOF/VEL/VOX, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 43
- States / cities
- Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Nab-Paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Fluorouracil, Atezolizumab, Cobimetinib, PEGPH20, BL-8040, Selicrelumab, Bevacizumab, RO6874281, AB928, Tiragolumab, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 12
- States / cities
- Duarte, California • San Francisco, California • New Haven, Connecticut + 8 more
- Conditions
- Emphysema, Pulmonary, Emphysema or COPD
- Interventions
- AeriSeal System
- Device
- Lead sponsor
- Pulmonx Corporation
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Loveland, Colorado • Hartford, Connecticut + 13 more
- Conditions
- Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant, Levodopa, Gait Impairment
- Interventions
- L-Dopa, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Nashville, Tennessee
- Conditions
- ALS, PLS, MND (Motor Neurone DIsease), Kennedy Disease, PMA - Progressive Muscular Atrophy, PBP - Progressive Bulbar Palsy
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2030
- U.S. locations
- 14
- States / cities
- Loma Linda, California • Los Angeles, California • Gainesville, Florida + 10 more
- Conditions
- Urge Urinary Incontinence, Overactive Bladder
- Interventions
- Botulinum toxin A (Botox A®), Solifenacin 5mg, Solifenacin 10mg, Trospium chloride
- Drug
- Lead sponsor
- NICHD Pelvic Floor Disorders Network
- Network
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 249 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • La Jolla, California • San Diego, California + 8 more
- Conditions
- Organic Acidemia, Methylmalonic Acidemia, Inborn Errors of Metabolism
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 1 Month to 115 Years
- Enrollment
- 2,275 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2004
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland • Pittsburgh, Pennsylvania
- Conditions
- Cubital Tunnel Syndrome
- Interventions
- Cubital tunnel release, Conservative Arm
- Procedure
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 7
- States / cities
- Bethel Park, Pennsylvania • Cranberry Township, Pennsylvania • Monroeville, Pennsylvania + 1 more
- Conditions
- Chronic Low Back Pain, Negative Affectivity
- Interventions
- Antidepressant, Enhanced Fear Avoidance Rehabilitation
- Drug · Other
- Lead sponsor
- Ajay Wasan, MD, Msc
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 308 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Chestnut Hill, Massachusetts • Rochester, Minnesota • Pittsburgh, Pennsylvania
- Conditions
- HIV Infections
- Interventions
- Raluridine
- Drug
- Lead sponsor
- Glaxo Wellcome
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 7
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Maitland, Florida + 4 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- ribavirin [Copegus], peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 24
- States / cities
- La Jolla, California • Long Beach, California • San Diego, California + 20 more
- Conditions
- Muscular Dystrophy, Duchenne
- Interventions
- SRP-5051
- Drug
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 7
- States / cities
- Sacramento, California • Gulf Breeze, Florida • Atlanta, Georgia + 4 more